Bayer tops pharma list for equality, diversity and inclusion

4 August 2022
bayer_flags_large

A new report by stakeholder intelligence firm alva has revealed the leaders in the pharma industry when it comes to equality, diversity and inclusion (EDI) - and Bayer (BAYN: DE) tops the list.

Post-pandemic, EDI is becoming a strategic imperative for pharma organisations as firms compete to recruit top talent.

"More diverse companies are better able to win top talent and improve their customer orientation, employee satisfaction and decision making"

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical